Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
2014; Ferrata Storti Foundation; Volume: 100; Issue: 2 Linguagem: Inglês
10.3324/haematol.2014.112557
ISSN1592-8721
AutoresKevin Song, Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau, Antonio Palumbo, Andrew Belch, Stephen Schey, Pieter Sonneveld, Lars Sternås, Xiaoyan Yu, Ramesh Amatya, Mara Silvia Monzini, Mohamed H. Zaki, Christian Jacques, Jesús F. San Miguel,
Tópico(s)Protein Degradation and Inhibitors
ResumoAdvances in treatments for multiple myeloma (MM) have resulted in improved survival. However, patients who have become refractory to novel agents have a poor prognosis, with a median overall survival (OS) of nine months, or as low as three months in the absence of further treatment after failure of
Referência(s)